Expertise in
19
conditions

Dr. Philip Bierman

Hematology
Office
987680 Nebraska Medical Ctr, 
Omaha, NE 
Expertise in
19
conditions
Office
987680 Nebraska Medical Ctr, 
Omaha, NE 

Overview

Philip Bierman is a Hematologist in Omaha, Nebraska. Dr. Bierman is highly rated in 19 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Gastric Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in NE

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
987680 Nebraska Medical Ctr, Omaha, NE 68198

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drug: Onalespib
Study Phase: Phase 2
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
View 5 Less Clinical Trials

64 Total Publications

Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
Journal: British journal of haematology
Published: January 11, 2023
Similar Doctors
Vijaya Bhatt
Expertise in
24
conditions
Dr. Vijaya Bhatt
Hematology
Expertise in
24
conditions
Dr. Vijaya Bhatt
Hematology

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (0.2 miles away)
402-559-5600
Languages Spoken:
English
See accepted insurances

Vijaya Bhatt is a Hematologist in Omaha, Nebraska. Dr. Bhatt is highly rated in 24 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
10
conditions
Dr. Wing Chan
Hematology
Expertise in
10
conditions
Dr. Wing Chan
Hematology

UNMC Physicians

988102 Nebraska Medical Ctr, 
Omaha, NE 
 (0.1 miles away)
402-559-4186
Languages Spoken:
English
See accepted insurances

Wing Chan is a Hematologist in Omaha, Nebraska. Dr. Chan is highly rated in 10 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Vitrectomy, and Bone Marrow Transplant.

James Armitage
Expertise in
21
conditions
Dr. James Armitage
Hematology
Expertise in
21
conditions
Dr. James Armitage
Hematology

UNMC Physicians

988102 Nebraska Medical Ctr, 
Omaha, NE 
 (0.1 miles away)
402-559-5600
Languages Spoken:
English
See accepted insurances

James Armitage is a Hematologist in Omaha, Nebraska. Dr. Armitage is highly rated in 21 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Endoscopy.

Frequently Asked Questions about Dr. Philip Bierman

How do I make an appointment with Dr. Philip Bierman?

You can book an appointment with Dr. Philip Bierman by calling their office at 402-559-5520. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Philip Bierman a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Philip Bierman is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Philip Bierman specialize in?

While Dr. Philip Bierman is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Gastric Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Philip Bierman participate in research or clinical trials?

Yes. Dr. Philip Bierman has published 64 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Philip Bierman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bierman's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile